Perspectives and challenges in regenerative medicine using plasma rich in growth factors

J Control Release. 2012 Jan 10;157(1):29-38. doi: 10.1016/j.jconrel.2011.07.004. Epub 2011 Jul 8.

Abstract

Plasma rich in growth factors (PRGF-Endoret) is an endogenous therapeutic technology that is gaining interest in regenerative medicine due to its potential to stimulate and accelerate tissue healing and bone regeneration. This autologous biotechnology is designed for the in situ delivery of multiple cellular modulators and the formation of a fibrin scaffold, thereby providing different formulations that can be widely used in numerous medical and scientific fields including dentistry, oral implantology, orthopedics, ulcer treatment and tissue engineering among others. Here we discuss the important progress that has been accomplished in this field. Furthermore, a comprehensive outlook of the intriguing therapeutic applications of this technology is presented.

Publication types

  • Review

MeSH terms

  • Animals
  • Fibrin / administration & dosage
  • Fibrin / chemical synthesis
  • Humans
  • Intercellular Signaling Peptides and Proteins / administration & dosage*
  • Intercellular Signaling Peptides and Proteins / blood*
  • Intercellular Signaling Peptides and Proteins / chemical synthesis
  • Regenerative Medicine / methods
  • Regenerative Medicine / trends*
  • Tissue Engineering / methods
  • Tissue Engineering / trends
  • Wound Healing / physiology

Substances

  • Intercellular Signaling Peptides and Proteins
  • Fibrin